SEC Comment Letter for Meihua International Medical Technologies Co., (MHUAF) — Feb 18, 2026
Meihua International Medical Technologies Co., Ltd.
Date: Feb. 18, 2026 · CIK: 0001835615 · Accession: 0000000000-26-001664
AI Filing Summary & Sentiment
Reasoning
Letter
Re: Meihua International Medical Technologies Co., Ltd. Draft Registration Statement on Form F-3 Submitted February 13, 2026 CIK No. 0001835615 Dear Leyi Lee:
February 18, 2026
Leyi Lee Chief Executive Officer Meihua International Medical Technologies Co., Ltd. 88 Tongda Road, Touqiao Town Guangling District, Yangzhou, 225000 People s Republic of China
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement and non-public draft submission on EDGAR at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Nicholas O'Leary at 202-551-4451 with any questions.
Sincerely,
Division of
Corporation Finance
Office of
Industrial Applications and Services
cc: Joan Wu, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> February 18, 2026 Leyi Lee Chief Executive Officer Meihua International Medical Technologies Co., Ltd. 88 Tongda Road, Touqiao Town Guangling District, Yangzhou, 225000 People s Republic of China Re: Meihua International Medical Technologies Co., Ltd. Draft Registration Statement on Form F-3 Submitted February 13, 2026 CIK No. 0001835615 Dear Leyi Lee: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement and non-public draft submission on EDGAR at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Nicholas O'Leary at 202-551-4451 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Joan Wu, Esq. </TEXT> </DOCUMENT>